- Home
- ON vs TAK Comparison
ON vs TAK Comparison
Compare ON & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ON | TAK |
|---|---|---|
| Founded | 1992 | 1781 |
| Country | United States | Japan |
| Employees | N/A | 47455 |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.9B | 52.4B |
| IPO Year | 2000 | N/A |
Fundamental Metrics
Financial Performance| Metric | ON | TAK |
|---|---|---|
| Price | $92.73 | $16.45 |
| Analyst Decision | Buy | |
| Analyst Count | 25 | 0 |
| Target Price | ★ $65.29 | N/A |
| AVG Volume (30 Days) | ★ 13.1M | 2.7M |
| Earning Date | 05-04-2026 | 05-13-2026 |
| Dividend Yield | N/A | ★ 3.24% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $5,878,300,000.00 | N/A |
| Revenue This Year | $7.93 | $0.16 |
| Revenue Next Year | $8.90 | $1.22 |
| P/E Ratio | ★ N/A | $41.25 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $44.56 | $12.99 |
| 52 Week High | $134.92 | $18.90 |
Technical Indicators
Market Signals| Indicator | ON | TAK |
|---|---|---|
| Relative Strength Index (RSI) | 42.40 | 54.67 |
| Support Level | $51.30 | $16.24 |
| Resistance Level | $133.67 | $16.48 |
| Average True Range (ATR) | 5.47 | 0.21 |
| MACD | -0.68 | 0.04 |
| Stochastic Oscillator | 18.33 | 56.13 |
Price Performance
Historical ComparisonAbout ON ON Semiconductor Corporation
Onsemi is a supplier of power semiconductors and sensors focused on the automotive and industrial markets. Onsemi is the second-largest power chipmaker in the world and the largest supplier of image sensors to the automotive market. While the firm used to be highly vertically integrated, it now pursues a hybrid manufacturing strategy for flexible capacity. Onsemi is pivoting to focus on emerging applications like electric vehicles, autonomous vehicles, industrial automation, and renewable energy.
About TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of)
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.5 trillion in fiscal 2025. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with about 50% from the US, 10% from Japan, 25% from Europe, and 15% from Canada.